Medindia

X

Treatment for Breast Cancer to take a New Turn

by Medindia Content Team on  July 14, 2006 at 2:09 PM Drug News   - G J E 4
Treatment for Breast Cancer to take a New Turn
Post Menopausal women with early breast cancer who have been receiving the 30-year-old tamoxifen treatment can now change to a more modern therapy with the drug, Arimidex under a new European licence granted to drug firm AstraZeneca.
Advertisement

The company AstraZeneca has stated that Arimidex, an aromatase inhibitor, will be made available to women who have already received a partial course of tamoxifen.The license for this switch over has been granted in Britain, Portugal, Germany, Spain and Italy.

Advertisement
Clinical research has revealed that Arimidex reduces the risk of return of breast cancer by an additional 26 percent on comparing with tamoxifen.

Thus far, Arimidex was only licensed for use immediately after breast cancer surgery, in patients who have been newly diagnosed with the disease. With the new licence Arimidex has become the first aromatase inhibitor to be approved in Europe for both primary use and subsequent to two to three years of tamoxifen.

Other rival companies Novartis AG and Pfizer Inc also make aromatase inhibitors.

Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All